.
Integrated Pharmacy
Study Course Description
Course Description Statuss:Approved
Course Description Version:12.00
Study Course Accepted:01.08.2024 13:17:09
Study Course Information | |||||||||
Course Code: | FKK_029 | LQF level: | Level 7 | ||||||
Credit Points: | 2.00 | ECTS: | 3.00 | ||||||
Branch of Science: | Basic Sciences of Medicine, including Pharmacy; Pharmacy | Target Audience: | Pharmacy | ||||||
Study Course Supervisor | |||||||||
Course Supervisor: | Inga Urtāne | ||||||||
Study Course Implementer | |||||||||
Structural Unit: | Department of Pharmaceutical Chemistry | ||||||||
The Head of Structural Unit: | |||||||||
Contacts: | Riga, 16 Dzirciema Street, Block A, 5th floor, Room No. 502, farmkkrsu[pnkts]lv, +371 67061544 | ||||||||
Study Course Planning | |||||||||
Full-Time - Semester No.1 | |||||||||
Lectures (count) | 8 | Lecture Length (academic hours) | 2 | Total Contact Hours of Lectures | 16 | ||||
Classes (count) | 8 | Class Length (academic hours) | 2 | Total Contact Hours of Classes | 16 | ||||
Total Contact Hours | 32 | ||||||||
Part-Time - Semester No.1 | |||||||||
Lectures (count) | 5 | Lecture Length (academic hours) | 2 | Total Contact Hours of Lectures | 10 | ||||
Classes (count) | 10 | Class Length (academic hours) | 2 | Total Contact Hours of Classes | 20 | ||||
Total Contact Hours | 30 | ||||||||
Study course description | |||||||||
Preliminary Knowledge: | Pharmaceutical chemistry, qualitative and quantitative analysis, organic and inorganic chemistry, pharmacology, physics, mathematics. | ||||||||
Objective: | • To promote the acquisition of knowledge about the main groups of drugs, their chemical structure and properties, the profile of the associated effect and side effects. • To promote skills of analysis and interpretation of the purpose of therapeutic action of medicinal substances. • To promote understanding of the influence of chemical structure on the mechanism of drug substance interaction, the importance of proper use. | ||||||||
Topic Layout (Full-Time) | |||||||||
No. | Topic | Type of Implementation | Number | Venue | |||||
1 | Integrated pharmacy, its relationship with chemistry, the role in the model of the health care system. | Lectures | 1.00 | auditorium | |||||
2 | Presentation of therapeutic data depending on the target audience. | Classes | 1.00 | auditorium | |||||
3 | Interpretation and analysis of phenotypic, pharmacokinetic, laboratory data from pilot studies. Development of research protocols. | Lectures | 1.00 | auditorium | |||||
4 | Informed patient consent. Development of research protocols. | Classes | 1.00 | auditorium | |||||
5 | Consequences of medication misuse (eg candidiasis) and solutions. | Lectures | 1.00 | auditorium | |||||
6 | Interpretation and analysis of laboratory data. | Classes | 1.00 | auditorium | |||||
7 | Therapeutic drug monitoring benefits and prerequisites for proper performance. | Lectures | 1.00 | auditorium | |||||
8 | Irrational use of the drug depending on the dosage form. | Classes | 1.00 | auditorium | |||||
9 | Anticoagulants and antiplatelet agents - factors that affect the monitoring of therapeutic drugs, dosage, frequency of use. | Lectures | 1.00 | auditorium | |||||
10 | Elements of consultation on the proper use of medicines. Disposal of the medicinal product after expiry date. | Classes | 1.00 | auditorium | |||||
11 | Active substances and excipients - areas of influence in the production process, in the operation of medicines | Lectures | 2.00 | auditorium | |||||
12 | Overview of drug interactions - benefits and risks. | Lectures | 1.00 | auditorium | |||||
13 | Pilot project presentations on individually selected topics | Classes | 3.00 | auditorium | |||||
Topic Layout (Part-Time) | |||||||||
No. | Topic | Type of Implementation | Number | Venue | |||||
1 | Integrated pharmacy, its relationship with chemistry, the role in the model of the health care system. | Lectures | 0.50 | auditorium | |||||
2 | Presentation of therapeutic data depending on the target audience. | Classes | 1.50 | auditorium | |||||
3 | Interpretation and analysis of phenotypic, pharmacokinetic, laboratory data from pilot studies. Development of research protocols. | Lectures | 0.50 | auditorium | |||||
4 | Informed patient consent. Development of research protocols. | Classes | 1.50 | auditorium | |||||
5 | Consequences of medication misuse (eg candidiasis) and solutions. | Lectures | 0.50 | auditorium | |||||
6 | Interpretation and analysis of laboratory data. | Classes | 1.00 | auditorium | |||||
7 | Therapeutic drug monitoring benefits and prerequisites for proper performance. | Lectures | 0.50 | auditorium | |||||
8 | Irrational use of the drug depending on the dosage form. | Classes | 1.50 | auditorium | |||||
9 | Anticoagulants and antiplatelet agents - factors that affect the monitoring of therapeutic drugs, dosage, frequency of use. | Lectures | 0.50 | auditorium | |||||
10 | Elements of consultation on the proper use of medicines. Disposal of the medicinal product after expiry date. | Classes | 1.50 | auditorium | |||||
11 | Active substances and excipients - areas of influence in the production process, in the operation of medicines | Lectures | 2.00 | auditorium | |||||
12 | Overview of drug interactions - benefits and risks. | Lectures | 0.50 | auditorium | |||||
13 | Pilot project presentations on individually selected topics | Classes | 3.00 | auditorium | |||||
Assessment | |||||||||
Unaided Work: | Individual presentations and scientific project according to the course topic using literature data. It is recommended to fill in the study course survey, evaluating the existing course content and creating proposals for updating the course. | ||||||||
Assessment Criteria: | Presentation according to the course topic (50%). Final written exam (50%). | ||||||||
Final Examination (Full-Time): | Exam (Written) | ||||||||
Final Examination (Part-Time): | Exam (Written) | ||||||||
Learning Outcomes | |||||||||
Knowledge: | On successful acquisition of the course the students will be able to: • will be able to evaluate the therapeutic activity of medicinal substances depending on the chemical structure, physico-chemical properties of the substance; • will be able to compare medicinal substances within one therapeutic group; • will be able to demonstrate knowledge of the predicted mechanism and incidence of adverse drug reactions; • will be able to assess the effect of non-medicinal factors on the therapeutic effect. | ||||||||
Skills: | On successful acquisition of the course the students will be able to: • to compile and systematize the current information regarding the medicinal products reviewed in the study course, their characteristics, properties, use in medicine; • to create presentations and research projects on medicinal substances, compiling the most up-to-date information from the SPCs and clinical trials published in recent years. | ||||||||
Competencies: | On successful completion of the study course, as a result of successful acquisition of the study course, students will be able to evaluate medicinal substances within one therapeutic group of medicinal products depending on the possibility of side effects and pharmacological effect; will be able to develop theoretical and practical analysis projects, interpret the obtained data in accordance with the specifics of the research topic. | ||||||||
Bibliography | |||||||||
No. | Reference | ||||||||
Required Reading | |||||||||
1 | Clinical Pharmacy and Therapeutics. / edited by Cate Whittlesea and Karen Hodson. 6th edition. Oxford: Elsevier, 2019. xiv, 1094 lpp. | ||||||||
2 | Maisto, Stephen A. Drug use and abuse / Stephen A. Maisto, Gerard J. Connors. 8th edition. Boston, MA : Cengage, 2019, xiv, 514 lpp. (brošēts). | ||||||||
3 | Oxford handbook of clinical pharmacy. / edited by Philip Wiffen, Marc Mitchell, Melanie Snelling, Nicola Stoner. 3rd edition. New York: Oxford University Press, 2017. xvi, 728 lpp. | ||||||||
Additional Reading | |||||||||
1 | Drug Delivery Systems / edited by Rakesh K. Tekade. London : Academic Press an imprint of Elsevier, [2019], 2020. xiii, 777 lpp. Advances in pharmaceutical product development and research. (iesiets). | ||||||||
2 | Integrated pharmacy case studies. / edited by Sally-Anne Francis, Felicity Smith, et.al. London: Pharmaceutical Press, 2015. xx, 432 lpp. | ||||||||
Other Information Sources | |||||||||
1 | Drugs | ||||||||
2 | Uptodate |